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Transcription factors of the Myc family regulate several homeostatic cell functions, and 
their role as proto-oncogenes has been the focus of interest for decades. We recently 
demonstrated that c-Myc is expressed in tumor-associated macrophages (TAMs) and 
regulates their phenotype and pro-tumoral activities in vivo. 
 
Main Text 
Myc transcription factors have long been known to affect many cellular processes, and 
recent experiments in Drosophila melanogaster have revealed yet another new facet of 
these proto-oncogenes. In fly embryos, ‘winner’ cells with high dMyc levels actively 
eliminate neighboring ‘loser’ cells with lower dMyc activity to become the predominant 
cells.1 This so-called ‘cell competition’ phenomenon, which seems to be part of a 
developmental size and quality control program,1 has also been proposed to play an 
important role in mammalian cancer development, where an initial tumoral cell with 
higher expression/activity of proto-oncogenes, such as c-Myc, might have certain 
advantages over non-tumoral neighboring cells (eg, increased metabolic rate, ability to 
resist apoptosis and proliferative activity).2, 3 The establishment of this competitive niche 
by the tumor cell suggests the possibility that other cells in the tumor microenvironment 
might gain an advantage over neighbors from expressing Myc. Indeed, we recently 
detected c-Myc expression in tumor associated macrophages (TAMs) from human 
colon cancer.4 
TAMs produce factors that promote angiogenesis, remodel tissue and dampen 
the anti-tumor immune response. Macrophages acquire specialized phenotypes in 
response to signals from the local microenvironment that polarize them toward a 
specific activation state.5 The tumor microenvironment has been shown to skew TAMs 
towards a wound healing/regulatory state that resembles several aspects of the 
alternatively-activated macrophage phenotype.6 We have recently shown that c-MYC is 
induced in human macrophages during in vitro alternative activation and controls the 
expression of several alternative-specific markers,4 thus suggesting that targeting c-Myc 
function in TAMs may limit tumor growth. To test this possibility in a pre-clinical setting, 
we crossed c-Mycfl/fl with LysMcre/+ mice to generate c-Mycfl/fl-LysMcre/+ mice  with 
myeloid cell-specific c-Myc inactivation (Mθ-c-Myc-KO).7 Compared with control 
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counterparts with intact c-Myc (c-Mycfl/fl), bone-marrow derived macrophages and 
peritoneal macrophages from Mθ-c-Myc-KO mice showed lower c-Myc levels (70-100% 
lower across all analyzed mice), while expression of c-Myc was unaffected in other 
tissues such as liver, kidney and testis. Under steady-state conditions, Mθ-c-Myc-KO 
mice exhibited normal immune system parameters, including numbers of total bone 
marrow cells and bone marrow hematopoietic precursors (eg, multipotent, multiple 
erythroid, granulocyte-macrophage, common myeloid and macrophage progenitors, and 
long-term and short-term hematopoietic stem cells). Moreover, Mθ-c-Myc-KO and 
control c-Mycfl/fl mice showed similar circulating cell counts, including total white blood 
cells, lymphocytes, neutrophils, classical- and non-classical monocytes, granulocytes, 
erythrocytes and platelets, as well as comparable numbers of similarly distributed 
infiltrated CD68+-macrophages in spleen, thymus and lymph nodes. 
To investigate cancer development in mice with macrophage-specific deletion of 
c-Myc, we injected B16-F10 melanoma cells carrying the firefly luciferase gene into the 
flanks of Mθ-c-Myc-KO and control c-Mycfl/fl mice and performed in vivo luciferase 
bioluminescent assays to assess tumor growth over time. These longitudinal studies 
together with post-mortem analysis performed 15 days after tumor cell inoculation 
revealed reduced tumor growth in Mθ-c-Myc-KO mice.7 Analysis of TAMs from Mθ-c-
Myc-KO tumors showed reduced expression of c-Myc with no effect on their 
proliferation or apoptosis rates, which, as in controls, were very low. Interestingly, 
detailed phenotyping by flow cytometry showed a higher abundance of mature 
Ly6ClowMHCIIhigh TAMs in controls, whereas TAMs isolated from Mθ-c-Myc-KO mice 
mostly showed an immature Ly6ChighMHCIIhigh phenotype. This observation is 
consistent with previous reports indicating that different tumor types or tumor grades are 
infiltrated by different TAM subtypes.8, 9 Our results provide evidence for a previously 
unrecognized role of c-Myc in the control of TAM maturation in vivo. It would be 
interesting to study if, over time, tumors from Mθ-c-Myc-KO mice eventually reach the 
size of tumors seen in controls and, at that point, if their TAMs have matured, somehow 
bypassing c-Myc inactivation. It should also be remembered that other transcription 
factors, such as NF-κB, are important drivers of cancer-related inflammation,10 therefore 
it would be interesting to analyze whether c-Myc and NF-κB act in parallel or 
sequentially and if they are expressed in the same macrophages or in distinct 
macrophage populations with different distributions within the tumor. 
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TAMs isolated from Mθ-c-Myc-KO mice also showed an attenuation of pro-
tumoral functions (such as reduced expression of VEGF, MMP9, and HIF1α), and this 
was associated with impaired tissue remodeling and angiogenesis in vivo, as assessed 
by molecular fluorescense tomography, and reduced development of new blood 
vessels, as revealed through the post-mortem confocal microscopy analysis of tumors.7 
Consistent with these findings, TAMs lacking c-Myc obtained in vitro by treating Mθ-c-
Myc-KO bone-marrow derived macrophages with tumor-conditioned medium showed 
reduced expression of VEGF, MMP9, and HIF1α than in vitro control TAMs with intact c-
Myc, and this was accompanied by decreased pro-tumoral activity, revealed by reduced 
metalloproteinase activity in zymogram assays, inhibition of endothelial cell proliferation 
and migration in wound healing assays, and inhibition of CD8+T lymphocyte 
proliferation. 
Our work identified c-Myc as an important regulator of TAM biology and 
maturation in vivo (Fig. 1). Compared with controls, Mθ-c-Myc-KO mice lacking c-Myc in 
myeloid cells exhibit defective tumor angiogenesis and reduced melanoma and 
fibrosarcoma development in xenographt models. These findings suggest c-Myc 
inactivation as an attractive strategy for cancer treatment. We believe that the new Mθ-
c-Myc-KO mouse model will also be useful for analyzing the role of c-Myc in other 
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Figure 1. Role of c-Myc in tumor-associated macrophages and cancer 
progression. After recruitment from peripheral blood, monocytes differentiate within the 
tumor into immature TAMs which do not display yet fully pro-tumoral functions. In 
control c-Mycfl/fl mice with intact c-Myc expression, TAMs mature and express high level 
of HIF1α, MMP9 and VEGF, which contribute to tissue remodeling, angiogenesis and 
tumor growth. Myeloid-specific deletion of c-Myc in Mθ-c-Myc-KO mice impairs TAM 
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